Trial · NCT00089895
EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED)
NCT00089895, Phase 3, Completed, Organon and Co; results first posted 2009-12-21
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED). Trials, record NCT00089895. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00089895
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED)
- NCT number
- NCT00089895
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 9,406 participants, actual
- Lead sponsor
- Organon and Co
- Conditions
- Myocardial Ischemia, Acute Coronary Syndrome
- Interventions
- Eptifibatide (Integrilin), Placebo
- First posted
- 2004-08-19
- Last updated
- 2024-05-17
- Results first posted
- 2009-12-21
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of the Composite of Death, Myocardial Infarction (MI), Recurrent Ischemia Requiring Urgent Revascularization (RI-UR), and Thrombotic Bail-out. | 96 hours after randomization | |
| Secondary | Incidence of the Composite of Death/MI. | 30 days after randomization |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Incidence of the Composite of Death, Myocardial Infarction (MI), Recurrent Ischemia Requiring Urgent Revascularization (RI-UR), and Thrombotic Bail-out. | 96 hours after randomization | Intent to treat population | percentage of participants | NUMBER |
| SECONDARY | Incidence of the Composite of Death/MI. | 30 days after randomization | Intent to treat population | percentage of participants | NUMBER |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Incidence of the Composite of Death, Myocardial Infarction (MI), Recurrent Ischemia Requiring Urgent Revascularization (RI-UR), and Thrombotic Bail-out. | Eptifibatide | 9.3 | percentage of participants | ||
| Incidence of the Composite of Death, Myocardial Infarction (MI), Recurrent Ischemia Requiring Urgent Revascularization (RI-UR), and Thrombotic Bail-out. | Placebo | 10.0 | percentage of participants | ||
| Incidence of the Composite of Death/MI. | Eptifibatide | 11.2 | percentage of participants | ||
| Incidence of the Composite of Death/MI. | Placebo | 12.3 | percentage of participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Eptifibatide | 4,722 | |
| Overall Study | STARTED | Placebo | 4,684 | |
| Overall Study | COMPLETED | Eptifibatide | 4,687 | |
| Overall Study | COMPLETED | Placebo | 4,642 | |
| Overall Study | NOT COMPLETED | Eptifibatide | 35 | |
| Overall Study | NOT COMPLETED | Placebo | 42 |
Source ClinicalTrials.gov
Adverse events182
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | ANAEMIA | Blood and lymphatic system disorders | Eptifibatide | 1 | 4,686 | 1 |
| serious | ANAEMIA | Blood and lymphatic system disorders | Placebo | 0 | 4,643 | 0 |
| serious | MICROCYTIC ANAEMIA | Blood and lymphatic system disorders | Eptifibatide | 1 | 4,686 | 1 |
| serious | MICROCYTIC ANAEMIA | Blood and lymphatic system disorders | Placebo | 0 | 4,643 | 0 |
| serious | PERICARDIAL EFFUSION | Cardiac disorders | Eptifibatide | 0 | 4,686 | 0 |
| serious | PERICARDIAL EFFUSION | Cardiac disorders | Placebo | 1 | 4,643 | 1 |
| serious | MIDDLE EAR INFLAMMATION | Ear and labyrinth disorders | Eptifibatide | 0 | 4,686 | 0 |
| serious | MIDDLE EAR INFLAMMATION | Ear and labyrinth disorders | Placebo | 1 | 4,643 | 1 |
| serious | ADRENOCORTICAL INSUFFICIENCY ACUTE | Endocrine disorders | Eptifibatide | 1 | 4,686 | 1 |
| serious | ADRENOCORTICAL INSUFFICIENCY ACUTE | Endocrine disorders | Placebo | 0 | 4,643 | 0 |
1 to 10 of 182Source ClinicalTrials.gov
See all 182 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Eptifibatide | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Eptifibatide | 0 | 4,686 |
| Total, other adverse events | Placebo | 0 | 4,643 |
| Total, serious adverse events | Eptifibatide | 66 | 4,686 |
| Total, serious adverse events | Placebo | 60 | 4,643 |
Source ClinicalTrials.gov
Papers15
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Eptifibatide vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00089895
GET https://conductscience.org/api/trials/v1/NCT00089895/events?page=2